MA41459A - Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l - Google Patents
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40lInfo
- Publication number
- MA41459A MA41459A MA041459A MA41459A MA41459A MA 41459 A MA41459 A MA 41459A MA 041459 A MA041459 A MA 041459A MA 41459 A MA41459 A MA 41459A MA 41459 A MA41459 A MA 41459A
- Authority
- MA
- Morocco
- Prior art keywords
- cd40l
- illnesses
- disorders
- methods
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111261P | 2015-02-03 | 2015-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41459A true MA41459A (fr) | 2017-12-12 |
Family
ID=56564599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041459A MA41459A (fr) | 2015-02-03 | 2016-02-01 | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
Country Status (15)
Country | Link |
---|---|
US (5) | US10106618B2 (fr) |
EP (2) | EP4071175A1 (fr) |
JP (3) | JP6797810B2 (fr) |
KR (1) | KR20170108024A (fr) |
CN (2) | CN108064168B (fr) |
AU (2) | AU2016215505B8 (fr) |
CA (1) | CA2974135A1 (fr) |
DK (1) | DK3253412T3 (fr) |
GB (1) | GB2552429A (fr) |
IL (2) | IL253571B (fr) |
MA (1) | MA41459A (fr) |
MX (2) | MX2017009694A (fr) |
RU (1) | RU2727646C2 (fr) |
SG (2) | SG10201912752QA (fr) |
WO (1) | WO2016126702A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9987356B2 (en) | 2011-03-11 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Anti-CD40 antibodies and methods of administering thereof |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
EP3307322B1 (fr) | 2015-09-04 | 2021-02-17 | Primatope Therapeutics Inc. | Anticorps humanisés anti-cd40 et leurs utilisations |
EP3630843A2 (fr) * | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Anticorps anti-ligand anti-cd40 thérapeutiques |
JP2022538674A (ja) * | 2019-07-01 | 2022-09-05 | トニックス ファーマ リミテッド | 抗cd154抗体およびその使用 |
EP3998282A4 (fr) * | 2019-07-08 | 2023-08-09 | Progen Co., Ltd. | Nouvelle protéine de fusion et son utilisation |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
AU2022205313A1 (en) * | 2021-01-06 | 2023-07-20 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
KR20230108156A (ko) * | 2022-01-10 | 2023-07-18 | 주식회사 금호에이치티 | Cd40l에 특이적으로 결합하는 항체 및 그의 용도 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
ES2143553T3 (es) | 1993-09-02 | 2000-05-16 | Dartmouth College | Anticuerpos anti-gp39 y sus utilizaciones. |
US5833987A (en) | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
TR200001246T2 (tr) | 1997-01-10 | 2000-07-21 | Biogen,Inc. | Anti-CD40L bileşikleri ile lupus nefritis tedavisi |
EE9900528A (et) | 1997-05-17 | 2000-06-15 | Biogen, Incorporated | CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks |
CN100352497C (zh) | 1998-04-03 | 2007-12-05 | 达特茅斯学院理事 | 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
EP1229935A1 (fr) | 1999-11-08 | 2002-08-14 | Idec Pharmaceuticals Corporation | Traitement de tumeurs malignes des cellules b a l'aide d'anticorps anti-cd40l associes a des anticorps anti-cd20, et/ou chimiotherapie et radiotherapie |
BR0108001A (pt) | 2000-02-01 | 2004-01-06 | Tanox Inc | Moléculas ativadoras de apc com ligação para cd-40 |
GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
AU2001261585B2 (en) * | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
CA2415100A1 (fr) | 2000-07-12 | 2002-01-17 | Idec Pharmaceutical Corporation | Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire |
CA2419841A1 (fr) | 2000-09-01 | 2002-03-07 | Biogen, Inc. | Nouveaux composes interrompant la fixation de cd40 et de cd154 et leur utilisation pour traiter des complications immunologiques |
AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
AU2003284968A1 (en) | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
WO2005003175A2 (fr) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Anticorps d'aglycosyle anti-cd154 (ligand cd40) et utilisations correspondantes |
EP1646654A1 (fr) | 2003-07-08 | 2006-04-19 | Genesto A/S | Element de liaison a une proteine a d'adhesine de surface pneumocoque |
EP1653801A4 (fr) | 2003-07-26 | 2007-05-30 | Biogen Idec Inc | Anticorps modifies presentant une affinite de liaison a l'antigene amelioree |
CA2536408A1 (fr) * | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes |
US20170166655A1 (en) | 2004-03-26 | 2017-06-15 | Xencor, Inc. | Novel immunoglobulin variants |
KR20070047327A (ko) | 2004-07-26 | 2007-05-04 | 비오겐 아이덱 엠에이 아이엔씨. | 항-cd154 항체 |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2006138316A2 (fr) | 2005-06-14 | 2006-12-28 | Biogen Idec Ma Inc. | Methodes permettant d'administrer des molecules au systeme nerveux central |
EP2431746A1 (fr) | 2005-11-17 | 2012-03-21 | Biogen Idec MA Inc. | Analyses d'agrégation de plaquettes |
CA2634547C (fr) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Formulations de proteine stables |
US7647438B1 (en) * | 2006-05-09 | 2010-01-12 | Integrated Device Technology, Inc. | Binary base address sorting method and device with shift vector |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
MX2009010120A (es) * | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
NZ581395A (en) * | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
GB0815788D0 (en) | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
DK2367849T3 (en) * | 2008-12-05 | 2018-01-22 | Als Therapy Development Inst | METHOD OF TREATING NEURODEGENERATIVE DISEASES |
EP2389192A4 (fr) | 2009-01-23 | 2013-01-16 | Biogen Idec Inc | Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation |
WO2012103218A1 (fr) | 2011-01-25 | 2012-08-02 | University Of South Florida | Modèle transgénique de la maladie d'alzheimer |
MX354359B (es) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
US9028826B2 (en) | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
WO2012138768A2 (fr) | 2011-04-04 | 2012-10-11 | Trustees Of Dartmouth College | Anticorps anti-cd154 ayant une liaison détériorée au fcr et/ou des propriétés de liaison au complément détériorée et leur utilisation dans des thérapies immunologiques |
BR112013026828A2 (pt) * | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
EP2748197A2 (fr) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Anticorps bispécifiques à fc en tandem |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
SG11201401385YA (en) * | 2011-10-13 | 2014-09-26 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40l |
AU2013260172B2 (en) | 2012-05-11 | 2017-11-23 | Medimmune Limited | CTLA-4 variants |
CN105121621B (zh) | 2012-10-18 | 2019-08-02 | 张永新 | 用于细胞动静态交替培养的生物反应器系统及其方法 |
EP3783017A1 (fr) * | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Variant de région fc |
KR20160124912A (ko) | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
BR112016023450A2 (pt) | 2014-04-25 | 2017-10-17 | Bristol Myers Squibb Co | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce |
WO2016028810A1 (fr) | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anticorps anti-cd40 et leurs utilisations |
MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
EP3630843A2 (fr) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Anticorps anti-ligand anti-cd40 thérapeutiques |
-
2016
- 2016-02-01 MA MA041459A patent/MA41459A/fr unknown
- 2016-02-02 MX MX2017009694A patent/MX2017009694A/es unknown
- 2016-02-02 SG SG10201912752QA patent/SG10201912752QA/en unknown
- 2016-02-02 EP EP22163613.7A patent/EP4071175A1/fr active Pending
- 2016-02-02 AU AU2016215505A patent/AU2016215505B8/en active Active
- 2016-02-02 KR KR1020177021029A patent/KR20170108024A/ko not_active Application Discontinuation
- 2016-02-02 GB GB1713871.0A patent/GB2552429A/en not_active Withdrawn
- 2016-02-02 JP JP2017540830A patent/JP6797810B2/ja active Active
- 2016-02-02 SG SG11201706258WA patent/SG11201706258WA/en unknown
- 2016-02-02 RU RU2017126997A patent/RU2727646C2/ru active
- 2016-02-02 CN CN201680008506.4A patent/CN108064168B/zh active Active
- 2016-02-02 WO PCT/US2016/016165 patent/WO2016126702A1/fr active Application Filing
- 2016-02-02 CA CA2974135A patent/CA2974135A1/fr active Pending
- 2016-02-02 CN CN202111202841.7A patent/CN114195895A/zh active Pending
- 2016-02-02 EP EP16747111.9A patent/EP3253412B1/fr active Active
- 2016-02-02 DK DK16747111.9T patent/DK3253412T3/da active
-
2017
- 2017-07-19 IL IL253571A patent/IL253571B/en unknown
- 2017-07-26 MX MX2022005655A patent/MX2022005655A/es unknown
- 2017-08-02 US US15/667,477 patent/US10106618B2/en active Active
-
2018
- 2018-09-07 US US16/125,317 patent/US10683356B2/en active Active
-
2020
- 2020-05-13 US US15/931,315 patent/US11014990B2/en active Active
- 2020-11-18 JP JP2020191310A patent/JP2021054826A/ja active Pending
-
2021
- 2021-05-17 US US17/322,486 patent/US11692040B2/en active Active
- 2021-11-03 IL IL287823A patent/IL287823A/en unknown
-
2022
- 2022-01-19 AU AU2022200323A patent/AU2022200323A1/en active Pending
- 2022-12-14 JP JP2022199466A patent/JP2023036717A/ja active Pending
-
2023
- 2023-06-26 US US18/341,202 patent/US20240043549A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41459A (fr) | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l | |
MA44886A (fr) | Compositions et méthode pour traiter des troubles acide-base | |
MA51316A (fr) | Compositions et méthodes permettant de traiter les troubles du snc | |
MA46315A (fr) | Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine | |
DK3485890T3 (da) | Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr | |
MA51074A (fr) | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine | |
MA42135A (fr) | Méthodes et trousses pour traiter la dépression | |
MA51315A (fr) | Compositions et méthodes permettant de traiter des troubles du snc | |
FR3012050B1 (fr) | Procede de formation d'une dispersion comprenant des gouttes, et appareil associe | |
ZA201805951B (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
PT3151859T (pt) | Controlo eficaz e eficiente do fosfato sérico para formação óssea ótima | |
HK1211151A1 (en) | Method and device for online registration and authentication | |
EA201792157A1 (ru) | Имидазопиразиноны в качестве ингибиторов pde1 | |
EP3219067A4 (fr) | Procédés et dispositifs pour négocier des paramètres de description de session | |
MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
ZA201702403B (en) | Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders | |
HK1222724A1 (zh) | 信息交互方法和裝置 | |
EP3197235A4 (fr) | Procédé et dispositif d'acquisition de paramètres de déchiffrement de signalisation sous sip | |
EP3232339A4 (fr) | Procédé et dispositif permettant de déterminer un plan d'exécution sql | |
EP3261975A4 (fr) | Dispositif de déraillement à sabot pour pont roulant et son procédé d'utilisation | |
IL274067A (en) | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | |
EP3110414A4 (fr) | Extraits de plante riches en xanthone ou composés dérivés de ceux-ci pour la modulation de maladies du système nerveux central et de troubles associés | |
EP3481432A4 (fr) | Diagnostic de maladies associées au gène col6 et procédés de traitement associés | |
SG10201606469QA (en) | System and method for controlling settlement | |
MA54630A (fr) | N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives |